Literature DB >> 18940593

In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.

Ryan M Drenan1, Sharon R Grady, Paul Whiteaker, Tristan McClure-Begley, Sheri McKinney, Julie M Miwa, Sujata Bupp, Nathaniel Heintz, J Michael McIntosh, Merouane Bencherif, Michael J Marks, Henry A Lester.   

Abstract

Alpha6-containing (alpha6*) nicotinic ACh receptors (nAChRs) are selectively expressed in dopamine (DA) neurons and participate in cholinergic transmission. We generated and studied mice with gain-of-function alpha6* nAChRs, which isolate and amplify cholinergic control of DA transmission. In contrast to gene knockouts or pharmacological blockers, which show necessity, we show that activating alpha6* nAChRs and DA neurons is sufficient to cause locomotor hyperactivity. alpha6(L9'S) mice are hyperactive in their home cage and fail to habituate to a novel environment. Selective activation of alpha6* nAChRs with low doses of nicotine, by stimulating DA but not GABA neurons, exaggerates these phenotypes and produces a hyperdopaminergic state in vivo. Experiments with additional nicotinic drugs show that altering agonist efficacy at alpha6* provides fine tuning of DA release and locomotor responses. alpha6*-specific agonists or antagonists may, by targeting endogenous cholinergic mechanisms in midbrain or striatum, provide a method for manipulating DA transmission in neural disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940593      PMCID: PMC2632732          DOI: 10.1016/j.neuron.2008.09.009

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  57 in total

1.  A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors.

Authors:  G E Cartier; D Yoshikami; W R Gray; S Luo; B M Olivera; J M McIntosh
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

2.  Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor.

Authors:  F Revah; D Bertrand; J L Galzi; A Devillers-Thiéry; C Mulle; N Hussy; S Bertrand; M Ballivet; J P Changeux
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

3.  Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording.

Authors:  P Calabresi; M G Lacey; R A North
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

4.  Nicotinic effects on the firing pattern of midbrain dopamine neurons.

Authors:  J Grenhoff; G Aston-Jones; T H Svensson
Journal:  Acta Physiol Scand       Date:  1986-11

5.  Frequency-dependent modulation of dopamine release by nicotine.

Authors:  Hui Zhang; David Sulzer
Journal:  Nat Neurosci       Date:  2004-05-16       Impact factor: 24.884

6.  Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area.

Authors:  W A Corrigall; K M Coen; K L Adamson
Journal:  Brain Res       Date:  1994-08-08       Impact factor: 3.252

7.  Numerical reconstruction of the quantal event at nicotinic synapses.

Authors:  J C Wathey; M M Nass; H A Lester
Journal:  Biophys J       Date:  1979-07       Impact factor: 4.033

8.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.

Authors:  J Michael McIntosh; Layla Azam; Sarah Staheli; Cheryl Dowell; Jon M Lindstrom; Alexander Kuryatov; James E Garrett; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

9.  Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors.

Authors:  C Labarca; M W Nowak; H Zhang; L Tang; P Deshpande; H A Lester
Journal:  Nature       Date:  1995-08-10       Impact factor: 49.962

10.  Schizophrenia and smoking: an epidemiological survey in a state hospital.

Authors:  J de Leon; M Dadvand; C Canuso; A O White; J K Stanilla; G M Simpson
Journal:  Am J Psychiatry       Date:  1995-03       Impact factor: 18.112

View more
  128 in total

1.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

2.  Modulation of gain-of-function α6*-nicotinic acetylcholine receptor by β3 subunits.

Authors:  Bhagirathi Dash; Ronald J Lukas
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 4.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

5.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

6.  Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.

Authors:  Alexandre Kuryatov; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

7.  Identification of N-terminal extracellular domain determinants in nicotinic acetylcholine receptor (nAChR) α6 subunits that influence effects of wild-type or mutant β3 subunits on function of α6β2*- or α6β4*-nAChR.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

Review 8.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

9.  Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors.

Authors:  Staci E Engle; J Michael McIntosh; Ryan M Drenan
Journal:  Neuropharmacology       Date:  2014-12-04       Impact factor: 5.250

10.  The Nicotinic α6-Subunit Selective Antagonist bPiDI Reduces Alcohol Self-Administration in Alcohol-Preferring Rats.

Authors:  Jirawoot Srisontiyakul; Hanna E Kastman; Elena V Krstew; Piyarat Govitrapong; Andrew J Lawrence
Journal:  Neurochem Res       Date:  2016-08-29       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.